PMID- 15748285
OWN - NLM
STAT- Publisher
LR  - 20201219
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 3
IP  - 1
DP  - 2005 Mar 4
TI  - HLA class I and II genotype of the NCI-60 cell lines.
PG  - 11
AB  - Sixty cancer cell lines have been extensively characterized and used by the 
      National Cancer Institute's Developmental Therapeutics Program (NCI-60) since the 
      early 90's as screening tools for anti-cancer drug development. An extensive 
      database has been accumulated that could be used to select individual cells lines 
      for specific experimental designs based on their global genetic and biological 
      profile. However, information on the human leukocyte antigen (HLA) genotype of 
      these cell lines is scant and mostly antiquated since it was derived from 
      serological typing. We, therefore, re-typed the NCI-60 panel of cell lines by 
      high-resolution sequence-based typing. This information may be used to: 1) 
      identify and verify the identity of the same cell lines at various institutions; 
      2) check for possible contaminant cell lines in culture; 3) adopt individual cell 
      lines for experiments in which knowledge of HLA molecule expression is relevant. 
      Since genome-based typing does not guarantee actual surface protein expression, 
      further characterization of relevant cell lines should be entertained to verify 
      surface expression in experiments requiring correct antigen presentation.
FAU - Adams, Sharon
AU  - Adams S
AD  - Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, 
      National Institutes of Health, Bethesda, Maryland, 20892, USA. 
      fmarincola@mail.cc.nih.gov.
FAU - Robbins, Fu-Meei
AU  - Robbins FM
FAU - Chen, Deborah
AU  - Chen D
FAU - Wagage, Devika
AU  - Wagage D
FAU - Holbeck, Susan L
AU  - Holbeck SL
FAU - Morse, Herbert C 3rd
AU  - Morse HC 3rd
FAU - Stroncek, David
AU  - Stroncek D
FAU - Marincola, Francesco M
AU  - Marincola FM
LA  - eng
PT  - Journal Article
DEP - 20050304
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
PMC - PMC555742
EDAT- 2005/03/08 09:00
MHDA- 2005/03/08 09:00
PMCR- 2005/03/04
CRDT- 2005/03/08 09:00
PHST- 2005/01/24 00:00 [received]
PHST- 2005/03/04 00:00 [accepted]
PHST- 2005/03/08 09:00 [pubmed]
PHST- 2005/03/08 09:00 [medline]
PHST- 2005/03/08 09:00 [entrez]
PHST- 2005/03/04 00:00 [pmc-release]
AID - 1479-5876-3-11 [pii]
AID - 10.1186/1479-5876-3-11 [doi]
PST - epublish
SO  - J Transl Med. 2005 Mar 4;3(1):11. doi: 10.1186/1479-5876-3-11.